Endothelin-1 and the pulmonary vascular response to altitude: a new therapeutic target?
Rubin
Lewis J
LJ
D000531:Altitude; D000532:Altitude Sickness / Q000188:drug therapy / Q000503:physiopathology* / Q000517:prevention & control; D000077300:Bosentan; D004231:Diuresis / Q000187:drug effects; D004311:Double-Blind Method; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood / Q000502:physiology*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D000860:Hypoxia / Q000209:etiology / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced; D009131:Muscle, Smooth, Vascular / Q000503:physiopathology; D024642:Potassium Channels, Voltage-Gated / Q000502:physiology*; D016032:Randomized Controlled Trials as Topic; D017466:Receptors, Endothelin / Q000502:physiology; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D014661:Vasoconstriction / Q000187:drug effects*; D016278:Ventricular Function, Right / Q000187:drug effects
D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D024642:Potassium Channels, Voltage-Gated; D017466:Receptors, Endothelin; D013449:Sulfonamides; D000077300:Bosentan